HilleVax
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Employees
- 90
- Market Cap
- $96M
- Website
- http://www.hillevax.com
- Introduction
HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.
Safety and Immunogenicity of HIL-214 in Healthy Japanese Infants
- Conditions
- Gastroenteritis
- Interventions
- Biological: PlaceboBiological: HIL-214
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- HilleVax
- Target Recruit Count
- 21
- Registration Number
- NCT06007781
- Locations
- ๐ฏ๐ต
Ohigesenseino Kodomo Clinic, Sapporo-Shi, Japan
๐ฏ๐ตFukui Aiiku Hospital, Fukui-Shi, Japan
๐ฏ๐ตIizuka Children's Clinic, Iizuka-Shi, Japan
Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults
- Conditions
- Gastroenteritis
- Interventions
- Biological: HIL-214
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- HilleVax
- Target Recruit Count
- 80
- Registration Number
- NCT05972733
- Locations
- ๐บ๐ธ
Clinical Research Atlanta, Stockbridge, Georgia, United States
๐บ๐ธPennisula Research Associates, Rolling Hills Estates, California, United States
Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines
- Conditions
- Gastroenteritis
- Interventions
- Biological: HIL-214Biological: Placebo
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- HilleVax
- Target Recruit Count
- 371
- Registration Number
- NCT05836012
- Locations
- ๐บ๐ธ
Velocity Clinical Research - Lafayette, Lafayette, Louisiana, United States
๐บ๐ธBoeson Research MSO, Missoula, Montana, United States
๐บ๐ธVelocity Clinical Research - Hastings, Hastings, Nebraska, United States
Efficacy and Safety of Two Doses of HIL-214 in Children
- Conditions
- Gastroenteritis
- Interventions
- Biological: HIL-214Biological: Placebo
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- HilleVax
- Target Recruit Count
- 3085
- Registration Number
- NCT05281094
- Locations
- ๐บ๐ธ
DM Clinical Research, Houston, Texas, United States
๐ต๐ชInstituto de Investigacion Nutricional, Lima, Peru
๐ต๐ฆCEVAXIN David, David, Chiriqui, Panama